![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 49, 45800-45805, December 7, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
, and
From the
CNRS, UPR 9023, CCIPE, 34094 Montpellier
Cedex 5, France, § EMBL, Meyerhofstrasse 1, Heidelberg D-69117, Germany, and ¶ Institut de
Génétique Moléculaire de Montpellier, UMR 5535 CNRS,
1919 Route de Mende, 34293 Montpellier Cedex 5, France
Received for publication, July 20, 2001, and in revised form, September 11, 2001
| |
ABSTRACT |
|---|
|
|
|---|
There is accumulating evidence that the
specificity of the transduction cascades activated by G protein-coupled
receptors cannot solely depend on the nature of the coupled G protein.
To identify additional structural determinants, we studied two
metabotropic glutamate (mGlu) receptors, the mGlu2 and mGlu7 receptors,
that are both coupled to Go proteins but are
known to affect different effectors in neurons. Thus, the mGlu2
receptor selectively blocks N- and L-type Ca2+ channels via
a protein kinase C-independent pathway, whereas the mGlu7 receptor
selectively blocks P/Q-type Ca2+ channels via a protein
kinase C-dependent pathway, and both effects are pertussis
toxin-sensitive. We examined the role of the C-terminal domain of these
receptors in this coupling. Chimeras were constructed by exchanging the
C terminus of these receptors and transfected into neurons. Different
chimeric receptors bearing the C terminus of mGlu7 receptor blocked
selectively P/Q-type Ca2+ channels, whereas chimeras
bearing the C terminus of mGlu2 receptor selectively blocked N- and
L-type Ca2+ channels. These results show that the C
terminus of mGlu2 and mGlu7 receptors is a key structural determinant
that allows these receptors to select a specific signaling pathway in neurons.
The physiological actions of most neurotransmitters are mediated
by activation of both ionotropic and G protein-coupled receptors (GPCRs1 or metabotropic
receptors). For instance, the metabotropic receptors activated by the
excitatory neurotransmitter, glutamate, play crucial roles in synaptic
plasticity, neurotoxicity, as well as neuroprotection. These effects
result from a large variety of regulations such as direct mediation of
glutaminergic synaptic transmission or modulation of neurotransmitter
release or membrane excitability (1). Transduction of extracellular
signals to intracellular responses via GPCR includes stimulation of the
receptor, activation of a trimeric G protein, and subsequent
mobilization of specific effectors. The regions of the receptor
involved in G protein activation have been studied extensively (2). The second intracellular loop of mGlu receptors is responsible for the
selective recognition of the G protein Eight genes encoding mGlu receptors have been identified and classified
into three groups, according to their sequence and intracellular
signaling. The group I mGlu receptors (mGlu1 and -5) are coupled to
Gq-like proteins and activate phospholipase C, whereas the
group II (mGlu2 and -3) and group III (mGlu4 and -6-8) receptors are
coupled to Gi/Go proteins and inhibit cAMP formation (5, 6). The signaling cascades of mGlu receptors seem,
however, to be far more complex than these consensual pathways. These
receptors can indeed activate cGMP phosphodiesterase (7), phospholipase
D (8), phospholipase A2 (9), and mitogen-activated protein
kinase cascades (10). Through these pathways, the mGlu receptors can
control ionic channel activities (11-13). Thus it is remarkable that
mGlu receptors activating the same group of G proteins inhibit distinct
Ca2+ channel subtypes (14-16). A series of studies
(17-20) have suggested that G protein To address this issue we studied two GPCRs, the mGlu2 and mGlu7
receptor subtypes. These receptors are both coupled to
Gi/Go proteins but trigger different second
messenger cascades, in cultured cerebellar granule cells. Thus, both
receptors activate a pertussis toxin-sensitive G protein, but the mGlu2
receptor selectively blocks N- and L-type Ca2+ channels
(15), whereas the mGlu7 receptor blocks the P/Q-type Ca2+
channels (27). Moreover, the effect of the mGlu7 (27) but not mGlu2
(15) receptor is PKC-dependent. To examine the possible role of the C-terminal intracellular domain of these receptors in
specifying their transduction cascade, the coupling to N- and L- or
P/Q-type Ca2+ channels of chimeric receptors bearing either
the C-terminal domain of mGlu2 or that of mGlu7 was examined in
cultured cerebellar granule cells. We found that the C terminus of the
mGlu7 receptor was necessary and sufficient to select a
PKC-dependent inhibitory pathway specific to the P/Q-type
Ca2+ channel, whereas the C terminus of the mGlu2 receptor
was necessary and sufficient for a PKC-independent inhibition of N- and
L-type Ca2+ channels. These findings reveal a new role of
the C terminus of mGlu2 and mGlu7 receptors in specifying their
respective transduction cascades downstream from the G protein activation.
Cell Culture--
Primary cultures of cerebellar cells were
prepared as described previously (28). Briefly, 1-week-old newborn mice
were decapitated and the cerebellum dissected. The tissue was then
gently triturated using fire-polished Pasteur pipettes, and the
homogenate was centrifuged at 500 rpm. The pellet was resuspended and
plated in tissue culture dishes previously coated with
poly-L-ornithine. Cells were maintained in a 1:1 mixture of
Dulbecco's minimum essential medium and F-12 nutrient (Life
Technologies, Inc.) supplemented with glucose (30 mM),
glutamine (2 mM), sodium bicarbonate (3 mM),
HEPES buffer (5 mM), decomplemented fetal calf serum
(10%), and 25 mM KCl to improve neuronal survival.
One-week-old cultures contained 1 × 106 cells.
Plasmids and Transfection--
The chimeric receptors were
constructed as follows. The mGlu2/7 and mGlu7/2 chimeras were obtained
by exchanging the C-terminal region proximal to the seventh
transmembrane domain of the mGlu7a receptor (beginning with HPELNVQKRK)
with its homologous mGlu2 receptor domain (beginning with QPQKNVVSHR)
(see Fig. 2), using the polymerase chain reaction overlap method (29).
The construction of the mGlu1/2 chimera containing the N-terminal
extracellular domain of the mGlu1 receptor and the heptahelical and
C-terminal regions of the mGlu2 receptor has been described previously
(30). The mGlu1/2/7 chimera was constructed by replacing the fragment encoding the 3'-half of the mGlu1/2 chimera by that of the mGlu2/7 chimera, using the BsrGI and XbaI restriction
sites of the mGlu2 receptor heptahelical domain coding sequence and the
pRK5 poly-linker, respectively.
The wild type and chimeric receptors were tested for their coupling to
G protein using the method that we described previously (31). Briefly,
inositol phosphate (IP) accumulation was measured in HEK-293 cells
co-transfected with the tested receptor and a recombinant G protein.
The mGlu1 receptor was co-transfected with a GHQ protein, whereas the
mGlu2, mGlu7a, mGlu2/7, mGlu7/2, mGlu1/2, and mGlu1/2/7 receptors were
co-transfected with a chimeric Gqi9 protein. In the
Gqi9 chimeric protein, the C-terminal 9 residues of the G
protein
Immediately before plating, cerebellar cultures were co-transfected
with the mGlu2 or mGlu7a receptors or one of the chimeras, and the
transfection marker green fluorescent protein (GFP)-containing plasmid,
pEGFP-N1 (CLONTECH), using the transfection lipid,
Transfast (32).
The wild type mGlu7a and chimeric mGlu7/2 receptors were tagged at
their N terminus with a Myc epitope, as described previously (27). The
presence of these Myc-tagged proteins at the cell surface was examined
in living (non-permeabilized) cultured neurons. Cells were exposed for
30 min at 37 °C to a polyclonal rabbit anti-Myc (1/300; ABR, Inc.)
primary antibody and then rinsed, fixed in a 4% paraformaldehyde, 0.1 M glucose-containing phosphate-buffered saline solution,
and exposed for 2 h at room temperature to a goat Texas
Red-conjugated anti-rabbit IgG (1/1000; Jackson ImmunoResearch). Cells
were then rinsed with phosphate-buffered saline and mounted on a glass
coverslip for observation on an Axiophot 2 Zeiss microscope. The
intensity of Myc immunolabeling was measured on the cell body using the
NIH Image program (Wayne Rasband). The ratio of total fluorescence of
the cell body area over background (noise) fluorescence was determined
in non-saturating conditions of the camera. The fluorescence values
were then averaged and compared between neurons transfected with
N-Myc-mGlu7a and -mGlu7/2 receptors.
Electrophysiology--
We used the whole-cell patch clamp
configuration to record Ba2+ current (IBa) from
GFP-expressing (mGlu receptor co-transfected) cerebellar granule cells,
after 9 ± 1 days in vitro, as described previously (32). The bathing medium contained (in mM)
BaCl2 (20), HEPES (10), tetraethylammonium acetate (10),
tetrodotoxin (3 × 10
Barium currents were evoked by 500-ms voltage clamp pulses, from a
holding potential of Materials--
DL-Aminophosphonobutyrate
(DL-AP4), dihydroxyphenyl glycine (DHPG), and MK-801 were
purchased from Tocris Cockson (UK). Nimodipine and GF109203X were
purchased from Research Biochemicals. Selective Blockade of Distinct Subtypes of Ca2+
Channels by the mGlu2 and mGlu7 Receptors--
The effect of mGlu2 and
mGlu7 receptors on Ba2+ currents (IBa) was studied in
cultured cerebellar granule cells transfected with GFP alone (control)
or in combination with either one of these receptors. In control
neurons, the selective P/Q-type (
As previously shown, the group III mGlu receptor agonist,
DL-AP4 (500 µM), had no significant effect on
IBa, in non-transfected or control (transfected with GFP alone)
cerebellar granule cells (27), indicating the absence of mGlu7 receptor
in the soma of these cells. After transfection, the mGlu7 receptor was
expressed in the cell body, which allowed us to study the effect of
this receptor on IBa (27). Under this condition, DL-AP4
selectively blocked IBa, and the inhibitory effect of this drug on
IBa2+ was additive with those of
In non-transfected (15, 34) as in mGlu2 receptor-transfected neurons
(Fig. 1D), the mGlu2 receptor agonist, LY354740 (1 µM), selectively inhibited N- and L-type Ca2+
channels. Because cultured cerebellar granule cells express native mGlu2 receptor, LY354740 could activate both the endogenous and the
transfected mGlu2 receptors. To rule out any activation of the
endogenous receptor, we constructed the so-called mGlu1/2 chimeric
receptor that harbored the N-terminal domain of the mGlu1 receptor and
the seven transmembranes with C-terminal domains of the mGlu2 receptor
(Fig. 2). This chimera was transfected in cultured cerebellar granule cells and activated with the group I mGlu
receptor agonist, DHPG (400 µM). Because of the presence of native mGluR1 receptors in granule neurons, DHPG was applied in the
presence of Bay36-7620 (10 µM), a non-competitive and
highly selective mGlu1 receptor antagonist that acts within the
transmembrane domains of this receptor (30). Thus, this antagonist
blocked the native (32) or recombinant mGlu1 receptor (Fig.
1E) but not the mGlu2 (30) or mGlu1/2 receptor (Fig.
1F). In neurons transfected with the mGlu1/2 receptor, DHPG
induced similar IBa inhibition (Fig. 1G) as the mGlu2
receptor agonist (Fig. 1D), indicating that the transfected
mGlu1/2 receptor displayed similar selective coupling to N- and L-type
Ca2+ channels, as the native mGlu2 receptor, in the same
cells.
In cerebellar granule cells co-transfected with the mGlu7 and mGlu1/2
receptors, the respective receptor agonists induced selective and
additive inhibitions of P/Q- and N-/L-type Ca2+ channels
(Fig. 3). Thus co-transfection and
overexpression of the mGlu1/2 and mGlu7 receptors did not change the
selective coupling of these receptors to distinct Ca2+
channels in the studied neurons.
We have shown previously that in neurons transfected with the mGlu7
receptor, intracellular injection of a specific antibody raised against
the G protein The C Terminus of mGlu2 and mGlu7 Receptors Determines Their
Coupling Selectivity to Ca2+ Channels--
We investigated
the role of the C terminus of mGlu2 and mGlu7 receptors in the
selective coupling of these receptors to Ca2+ channels. To
this end, we exchanged the C terminus of the mGlu2 and mGlu7 receptors
to obtain the reciprocal mGlu2/7 and mGlu7/2 chimeras (Fig. 2,
A and B). The amino acid sequences of the
exchanged C-terminal regions are represented in Fig. 2C. In
mGlu7/2-transfected neurons, DL-AP4 inhibited 32% of IBa.
The remaining IBa was not significantly affected by
In mGlu2/7-transfected cells, LY354740 blocked 55% of IBa. Following
this inhibition, neither
We verified that the switch in the coupling to Ca2+
channels by exchanging mGlu receptor C termini resulted from a switch
in the receptor signaling pathway. The PKC inhibitor, GF-109203X (10 µM), strongly reduced the amount of mGlu7 or mGlu1/2/7
receptor-induced IBa inhibition without affecting mGlu2, or mGlu1/2, or
mGlu7/2 receptor-induced inhibition (Fig.
5). These results indicated that the C
terminus of mGlu2 and mGlu7 receptors specified the receptor signaling
pathway, and thus the selectivity of the receptor coupling to
Ca2+ channels, in neurons.
As reviewed in Table I, our results
show for the first time that the C terminus of mGlu2 and -7 receptors
is a molecular determinant involved in the selectivity of coupling to
specific effectors. To characterize this molecular feature, we used
chimeric receptors transfected in neuronal cultures. This type of
preparation provided a more physiological environment than classical
heterologous expression systems, notably for studying receptor
transduction signaling, because the natural transduction pathway and
effectors were expected to be present in our model. Moreover, we
verified that the transfection and overexpression of the studied wild
type receptors did not modify their signaling pathway and coupling to
Ca2+ channels as compared with the endogenous receptors. We
also verified that the differences observed between functional
responses of the wild type and corresponding chimeric receptors did not
result from differential cell surface expression of these
receptors.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
subunit (3, 4), whereas all
other receptor intracellular segments control the coupling efficacy
(4).
subunits may be essential
for the specific coupling of various metabotropic neurotransmitter
receptors to Ca2+ channels, but others (21-24) have shown
that the same G protein 
subunit combination can inhibit
different Ca2+ channel subtypes and vice versa. The mGlu
receptors have even been shown to activate directly effectors and
generate cellular responses independently of G protein activation (25).
This large variety of mGlu receptor actions together with the limited
number of functional G protein subunit combinations (26) suggest that the signaling cascade specificity of a given GPCR cannot arise solely
from the nature of the activated G protein. The aim of the present
study was to examine whether receptor structural determinants are
involved in the specificity of GPCR signaling.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
q subunit were replaced by those of the G
protein
i2 subunit, enabling the coupling of the
receptors to phospholipase C (4, 30, 31).
4), glucose (10), sodium
acetate (120), and MK-801 (1 × 10
3), adjusted to pH
7.4 with NaOH and 330 mosm with sodium acetate. Drug solutions
were prepared in this medium, and pH was readjusted to 7.4. The
N-methyl-D-aspartic acid receptor channel
blocker, MK-801 (1 µM), was added to all solutions to
avoid activation of this receptor by the D-isoform of
DL-AP4.2 Patch
pipettes were made from borosilicate glass, coated with Sylgard, and
their tip fire-polished. Pipettes had resistances of 3-5 megohms when
filled with the following internal solution (in mM): cesium
acetate (100), MgCl2 (2), HEPES (10), glucose (15), CsCl
(20), EGTA (20), Na2ATP (2), and cAMP (1) adjusted to pH
7.2 with CsOH and 300 mosM with cesium acetate.
80 mV, to a test potential of 0 mV, applied at a
rate of 0.1 Hz. Current signals were recorded using an Axopatch 200 amplifier (Axon Instruments, Foster City, CA), filtered at 1 kHz with
an 8-pole Bessel filter, and sampled at 3 kHz on a Pentium II PC
computer. Analyses were performed using the pClamp6 program of Axon
Instruments. Barium currents were measured at their peak amplitude and
values expressed as mean ± S.E. of the indicated number
(n) of experiments. The Student's t test
(p
0.05) was used for comparison.
-Agatoxin-IVA and
-conotoxin-GVIA were from Alomone Labs (Israel). LY354740 was a
generous gift from D. Schoepp (Lilly). An antibody raised against the
Go protein was a generous gift from V. Homburger. This
antibody has been shown previously to recognize specifically the G
protein
o subunit but not the
i subunit
(33).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-agatoxin-IVA; 250 nM),
N-type (
-conotoxin-GVIA; 1 µM) and L-type (nimodipine; 1 µM) Ca2+ channel blockers inhibited 41, 10, and 22% IBa, respectively. The remaining 27% IBa resulted
from activation of the R-type Ca2+ channels. Similar data
were obtained in non-transfected neurons (15) or neurons co-transfected
with GFP and either the mGlu7 (Fig.
1A) or mGlu2 (Fig.
1C) receptors. These results indicated that the transfection
procedure did not alter functional expression of the native
Ca2+ channels.

View larger version (34K):
[in a new window]
Fig. 1.
Inhibitory effects of transfected mGlu2,
mGlu7, or mGlu1/2 receptors on IBa. A-D and
G, inhibitory effects of the indicated drugs and toxins (250 nM
-agatoxin-IVA, 1 µM
-conotoxin-GVIA,
1 µM nimodipine, 500 µM DL-AP4,
1 µM LY354740, and 400 µM DHPG) obtained in
cultured cerebellar granule cells co-transfected with GFP and either
the mGlu7 (A and B), mGlu2 (C and
D), or mGlu1/2 receptor (G). Each bar
of histogram represents the mean (± S.E.) of at least eight
experiments. E and F, Bay36-7620 is selective for
the mGlu1 over the mGlu1/2 receptor. IP accumulation was measured in
HEK-293 cells transiently expressing mGlu1 (E) or mGlu1/2
(F) receptors and incubated in the presence of 1 mM glutamate (Glu), 10 µM Bay36-7620, or
both. The data are expressed as the percentage of basal IP formation
obtained in the absence of drug (Basal). Each bar
of histogram represents the mean ± S.E. of four independent
experiments performed in triplicate.
-conotoxin-GVIA and
nimodipine but not with that of
-agatoxin-IVA (Fig. 1B).
These results indicated that the transfected mGlu7 receptor blocked
specifically P/Q-type Ca2+ channels.

View larger version (24K):
[in a new window]
Fig. 2.
Schematic representation of wild type and
chimeric mGlu receptors. A, the circle,
horizontal box, and vertical box represent the
extracellular N-terminal, transmembrane, and intracellular C-terminal
domains of mGlu receptors, respectively. B, schematic
representation of the wild type and chimeric constructions.
C, amino acid sequence of the exchanged C-terminal domains
of mGlu2 and mGlu7 receptors.

View larger version (23K):
[in a new window]
Fig. 3.
Additive inhibitory effects of the mGlu1/2
and mGlu7 receptors on IBa, in mGlu1/2, and mGlu7 co-transfected
cerebellar granule cells. A, IBa recorded in a
co-transfected neuron, in the absence (control) or presence
of the indicated drugs. B, inhibitory effects of the mGlu7
(DL-AP4) and mGlu1/2 (DHPG) agonists
on IBa. Each bar of histogram represents the mean (± S.E.)
of at least seven experiments. Note that the mGlu7 and mGlu1/2 agonists
induced similar IBa inhibitions as in neurons transfected with mGlu7 or
mGlu1/2 alone (Fig. 1, B and G). C,
time course of the inhibitory effect of the indicated drugs and
toxins.
o subunit blocked the inhibitory effect of
DL-AP4 on IBa, without significantly altering the current density in the absence of agonist (27). Here, the same antibody injected in mGlu2-transfected neurons antagonized the inhibitory effect
of LY354740 on IBa (LY354740 induced 12 ± 2% inhibition; n = 7). The boiled antibody was without effect.
These results showed that both mGlu2 and mGlu7 receptors acted via a
Go protein.
-conotoxin-GVIA
or nimodipine. However, the current was further depressed by
-agatoxin-IVA (Fig. 4A) and
in similar proportions as in control cells (compare with Fig. 1A). These results show that exchanging the C terminus of
mGlu7 receptor with the one of mGlu2 receptor switched the selective coupling of the mGlu7 receptor to that of the mGlu2 receptor. No
statistical difference was observed between cell surface immunolabeling of the mGlu7 and mGlu7/2 receptors (immunofluorescence values: 7.0 ± 0.6, n = 10; 7.4 ± 0.8, n
= 10, respectively; p
0.05), indicating
that the difference observed in the selective coupling of these
receptors to Ca2+ channels could not result from
differential cell surface expression of the receptors.

View larger version (31K):
[in a new window]
Fig. 4.
Inhibitory effect of the mGlu7/2, mGlu2/7, or
mGlu1/2/7 receptors on IBa in transfected cerebellar granule
cells. A-C, inhibitory effects of agonist and toxins
on IBa. Each bar of histogram represents the mean (± S.E.)
of at least 10 experiments. D-F, inhibitory effect of
reversed applications of the agonists and toxins on IBa. Each
graph was obtained from a different single neuron and was
representative of at least 5 other cells. Note the selective blockade
of N- and L-type IBa by the mGlu7/2 receptor agonist
(DL-AP4) in A and D, N-;
L- and P/Q-type IBa by the mGlu2/7 receptor agonist (LY354740) in
B and E; P/Q-type IBa by the mGlu1/2/7 receptor
agonist (DHPG) in C and F.
-conotoxin-GVIA, nimodipine, nor
-agatoxin-IVA further inhibited IBa (Fig. 4B). These
results were consistent with a blockade of P/Q-type as well as N- and L-type Ca2+ channels by the mGlu2 receptor agonist,
probably through activation of the transfected mGlu2/7 and native mGlu2
receptors, respectively. To avoid any activation of the endogenous
mGlu2 receptor, we transfected the mGlu1/2/7 receptor construct (N
terminus of mGlu1 with the seven transmembrane domains of mGlu2 and the
C terminus of mGlu7; Fig. 2) and stimulated this chimera with DHPG, in
the presence of Bay36-7620. Under these conditions, DHPG inhibited 34%
of IBa. Application of
-conotoxin-IVA and nimodipine, in the
presence of these drugs, inhibited 9 and 23% of total IBa, whereas
-agatoxin-IVA had no significant additional effect (Fig.
4C). These results indicated that DHPG blocked selectively
P/Q-type Ca2+ channels. In a separate series of
experiments, an initial application of a given channel blocker was
immediately followed by application of the transfected receptor
agonist. Thus, in mGlu7/2 receptor-transfected cells, after blockade of
N- and L-type Ca2+ channels with
-conotoxin-GVIA and
nimodipine, respectively, the resistant IBa was not affected by
subsequent application of DL-AP4 (Fig. 4D). In
mGlu2/7-transfected cells, after blockade of N-, L-, and P/Q-type
Ca2+ channels with
-conotoxin-GVIA, nimodipine, and
-agatoxin-IVA, the drug/toxin-insensitive IBa was not further
depressed by application of LY354740 (Fig. 4E). Finally, in
mGlu1/2/7 receptor-transfected cells, after blockade of P/Q-type
Ca2+ channels with
-agatoxin-IVA, DHPG did not further
inhibit the remaining IBa (Fig. 4F). Altogether these
results indicated that exchanging the C terminus of mGlu2 with the one
of mGlu7 receptor switched the selective coupling of mGlu2 to the one
of mGlu7 receptor.

View larger version (48K):
[in a new window]
Fig. 5.
Involvement of a PKC pathway in mGlu7- and
mGlu1/2/7- but not in mGlu2-, mGlu1/2-, or mGlu7/2-mediated inhibitions
of IBa in transfected cerebellar granule cells. Mean (± S.E.;
n = 5 to 10) fractional reduction of the IBa induced by
DL-AP4 (500 µM) in mGlu7 and mGlu7/2
transfected neurons, LY354740 (1 µM) in mGlu2 transfected
neurons and DHPG (400 µM), in mGlu1/2 and mGlu1/2/7
transfected neurons, treated or not for 30 min with the PKC inhibitor,
GF109203X (10 µM).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Results summary
The existence of a large number of GPCR-mediated signaling pathways,
with respect to the limited number of functional G protein subunits,
raises the question of how a particular receptor is selectively coupled
to a given effector. We provide insight into this question by showing
that the C terminus of two Go protein-coupled mGlu
receptors is a key molecular determinant for selecting a specific
signaling pathway. This part of the mGlu receptors has not been
reported to be involved in the coupling specificity to G protein
subunit (3, 4). This was consistent with the idea that activation of a
specific class of G protein by a given GPCR does not seem to be
sufficient to determine the specificity of the receptor transduction
pathway. For instance in sympathetic neurons, various neurotransmitter
receptors have been shown to inhibit N-type Ca2+ channels
whatever the nature of the
and 
subunits of the activated
recombinant G protein (21).
Consistent with our findings, a growing body of evidence suggests that in addition to the G protein activation, the C terminus of mGlu receptors plays an essential role in the selection of a specific signaling pathway. Because the C terminus of the receptor is the target of a number of kinases and intracellular proteins (35), these factors may support the selectivity of the receptor coupling. The two following examples are in favor of this hypothesis. A first example is the differential coupling of the mGlu5 receptor to either combined IP3 and cAMP or single IP3 pathways, depending on the PKC-mediated phosphorylation of two C-terminal serine residues at positions 881 and 890 (35-37). A second example is the PKC-mediated phosphorylation of a C-terminal threonine residue, at position 840 of the mGlu5 receptor. This phosphorylation is responsible for generation of Ca2+ oscillations in response to agonist. By contrast, the mGlu1a receptor displays an aspartate residue in this corresponding position and triggers a single peak Ca2+ response (38). Therefore, because of differential phosphorylation of their C terminus, mGlu1 and mGlu5 receptors can display different signaling cascades, although both receptors activate Gq proteins. The same might apply to mGlu2 and mGlu7 receptors, but no such functional specific differential phosphorylation sites have been reported so far for these receptors. Therefore, such a hypothesis would need further specific examination.
Proteins that interact differentially with the C terminus of mGlu2 and
mGlu7 receptors are also good candidates for selective activation of
different transduction pathways. To our knowledge, no protein has been
shown to interact directly with the C terminus of the mGlu2 receptor.
By contrast, the mGlu7 receptor C terminus displays binding sites for a
number of intracellular proteins (39). Indeed, both calmodulin and
G
subunits can bind, in a mutually exclusive manner, to a
subdomain in the C terminus of the mGlu7 receptor. Thus, dissociation
of the 
subunits from the activated G protein interacts with the
mGlu7 receptor C terminus. However, the binding of calmodulin to the
receptor will promote dissociation of the G protein 
subunits
from the receptor, thus making these subunits available for inhibiting
P/Q-type Ca2+ channels (40). Therefore, it appears that
inhibition of Ca2+ channels by the mGu7 receptor may not
solely depend on activation of a G protein but also on protein-protein
interaction in the C terminus of the receptor. A second candidate is
the PDZ domain-containing protein, protein interacting with C kinase 1 (PICK1). This protein interacts with the very last 3 C-terminal amino
acids of the mGlu7a receptor (41-43). The PDZ domain of PICK1 also
interacts with PKC
(44) thus creating a functional complex
comprising the mGlu7 receptor, a PICK1 dimer and PKC
(42). These
associations may be functionally important in the
PKC-dependent coupling of the mGlu7 receptor to P/Q-type
Ca2+ channels.
Our results may be of particular interest in understanding the
physiological significance of alternative splicing of GPCRs. Strikingly, the variable part in GPCR splicing, including the class of
mGlu receptors (12), is their C-terminal domain. For example, the
natural mGlu7a receptor splice variant, mGluR7b, is generated by an
out-of-frame insertion in the C terminus that results in the
replacement of the last 16 amino acids of the mGlu7a receptor by 23 different amino acids (45, 46). According to our finding that the C
terminus of mGlu receptors plays a key role in the receptor coupling to
specific effectors, different mGlu receptor splice variants could lead
to different signaling pathways, depending on the splice site choice.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Anne Cohen-Solal for technical assistance and Dr. J. Saugstad (Atlanta, GA) for the generous gift of the mGlu7a receptor cDNA.
| |
FOOTNOTES |
|---|
* This work was supported by grants from the CNRS, Foundation pour la Recherde Médicale, Bayer (to J. B.), Association Française contre les Myopathies (to L. F.), Retina France, Ligue Nationale Contre le Cancer (to V. C.), Action Incitative Physique et Chemie du Vivant from CNRS (00-134), and Moléculo et Cibles Thérapeutiques program from INSERM and CNRS (to J. P. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: CNRS, UPR
9023, CCIPE, 141 Rue de la Cardonille, 34000 Montpellier, France. Tel.: 33 467 142 945; Fax: 33 467 542 432; E-mail:
fagni@bacchus.montp.inserm.fr.
Published, JBC Papers in Press, October 2, 2001, DOI 10.1074/jbc.M106876200
2 J. Perroy, G. J. Gutierrez, V. Coulon, J. Bockaert, J.-P. Pin, and L. Fagni, unpublished observations.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GPCR, G protein-coupled receptor; mGlu, metabotropic glutamate; PKC, protein kinase C; DHPG, dihydroxyphenyl glycine; GFP, green fluorescent protein; DL-AP4, DL-aminophosphonobutyrate; IP, inositol phosphate.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Pin, J. P., and Bockaert, J. (1995) Curr. Opin. Neurobiol. 5, 342-349[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Bourne, H. R. (1997) Curr. Opin. Cell Biol. 9, 134-142[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Pin, J. P., Joly, C., Heinemann, S. F., and Bockaert, J. (1994) EMBO J. 13, 342-348[Medline] [Order article via Infotrieve] |
| 4. |
Gomeza, J.,
Joly, C.,
Kuhn, R.,
Knopfel, T.,
Bockaert, J.,
and Pin, J. P.
(1996)
J. Biol. Chem.
271,
2199-2205 |
| 5. | Prezeau, L., Carrette, J., Helpap, B., Curry, K., Pin, J. P., and Bockaert, J. (1994) Mol. Pharmacol. 45, 570-577[Abstract] |
| 6. | Conn, P. J., and Pin, J. P. (1997) Annu. Rev. Pharmacol. Toxicol. 37, 205-237[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Nawy, S., and Jahr, C. E. (1990) Nature 346, 269-271[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Boss, V., and Conn, P. J. (1992) J. Neurochem. 59, 2340-2343[Medline] [Order article via Infotrieve] |
| 9. | Dumuis, A., Pin, J. P., Oomagari, K., Sebben, M., and Bockaert, J. (1990) Nature 347, 182-184[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Ferraguti, F., Baldani-Guerra, B., Corsi, M., Nakanishi, S., and Corti, C. (1999) Eur. J. Neurosci. 11, 2073-2082[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Kammermeier, P. J., and Ikeda, S. R. (1999) Neuron 22, 819-829[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Fagni, L., Chavis, P., Ango, F., and Bockaert, J. (2000) Trends Neurosci. 23, 80-88[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Charpak, S., Gähwiler, B. H., Do, K. Q., and Knöpfel, T. (1990) Nature 347, 765-767[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Sahara, Y., and Westbrook, G. L. (1993) J. Neurosci. 13, 3041-3050[Abstract] |
| 15. | Chavis, P., Fagni, L., Bockaert, J., and Lansman, J. B. (1995) Neuropharmacology 34, 929-937[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Ikeda, S. R., Lovinger, D. M., McCool, B. A., and Lewis, D. L. (1995) Neuron 14, 1029-1038[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Garcia, D. E.,
Li, B.,
Garcia-Ferreiro, R. E.,
Hernandez-Ochoa, E. O.,
Yan, K.,
Gautam, N.,
Catterall, W. A.,
Mackie, K.,
and Hille, B.
(1998)
J. Neurosci.
18,
9163-9170 |
| 18. | Kleuss, C., Hescheler, J., Ewel, C., Rosenthal, W., Schultz, G., and Wittig, B. (1991) Nature 353, 43-48[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Kleuss, C., Scherubl, H., Hescheler, J., Schultz, G., and Wittig, B. (1992) Nature 358, 424-426[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Kleuss, C.,
Scherubl, H.,
Hescheler, J.,
Schultz, G.,
and Wittig, B.
(1993)
Science
259,
832-834 |
| 21. |
Jeong, S. W.,
and Ikeda, S. R.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
907-912 |
| 22. |
Jeong, S. W.,
and Ikeda, S. R.
(2000)
J. Neurosci
20,
4489-4496 |
| 23. |
Jeong, S. W.,
and Ikeda, S. R.
(1999)
J. Neurosci.
19,
4755-4761 |
| 24. |
Shapiro, M. S.,
Loose, M. D.,
Hamilton, S. E.,
Nathanson, N. M.,
Gomeza, J.,
Wess, J.,
and Hille, B.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
10899-10904 |
| 25. | Heuss, C., and Gerber, U. (2000) Trends Neurosci. 23, 469-475[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Morris, A. J.,
and Malbon, C. C.
(1999)
Physiol. Rev.
79,
1373-1430 |
| 27. |
Perroy, J.,
Prézeau, L.,
De Waard, M.,
Shigemoto, R.,
Bockaert, J.,
and Fagni, L.
(2000)
J. Neurosci.
20,
7896-7904 |
| 28. | Van Vliet, B. J., Sebben, M., Dumuis, A., Gabrion, J., Bockaert, J., and Pin, J. P. (1989) J. Neurochem. 52, 1229-1239[Medline] [Order article via Infotrieve] |
| 29. | Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Caroll, F.,
Stolle, A.,
Beart, P. M.,
Voerste, A.,
Brabet, I.,
Mauler, F.,
Joly, C.,
Antonicek, H.,
Bockaert, J.,
Muller, T.,
Pin, J. P.,
and Prézeau, L.
(2001)
Mol. Pharmacol.
59,
965-973 |
| 31. |
Parmentier, M. L.,
Joly, C.,
Restituito, S.,
Bockaert, J.,
Grau, Y.,
and Pin, J. P.
(1998)
Mol. Pharmacol.
53,
778-786 |
| 32. | Ango, F., Albani-Torregrossa, S., Joly, C., Robbe, D., Michel, J. M., Pin, J. P., Bockaert, J., and Fagni, L. (1999) Neuropharmacology 38, 793-803[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Lledo, P. M., Homburger, V., Bockaert, J., and Vincent, J. D. (1992) Neuron 8, 455-463[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Chavis, P., Shinozaki, H., Bockaert, J., and Fagni, L. (1994) J. Neurosci. 14, 7067-7076[Abstract] |
| 35. | De Blasi, A., Conn, J. P., Pin, J. P., and Nicoletti, F. (2001) Trends Pharmacol. Sci. 22, 114-120[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Gereau, R. W. T., and Heinemann, S. F. (1998) Neuron 20, 143-151[CrossRef][Medline] [Order article via Infotrieve] |
| 37. |
Francesconi, A.,
and Duvoisin, R. M.
(1998)
J. Biol. Chem.
273,
5615-5624 |
| 38. | Kawabata, S., Tsutsumi, R., Kohara, A., Yamaguchi, T., Nakanishi, S., and Okada, M. (1996) Nature 383, 89-92[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Dev, K. K., Nakanishi, S., and Henley, J. M. (2001) Trends Pharmacol. Sci. 22, 355-361[CrossRef][Medline] [Order article via Infotrieve] |
| 40. |
O'Connor, V.,
El Far, O.,
Bofill-Cardona, E.,
Nanoff, C.,
Freissmuth, M.,
Karschin, A.,
Airas, J. M.,
Betz, H.,
and Boehm, S.
(1999)
Science
286,
1180-1184 |
| 41. | Boudin, H., Doan, A., Xia, J., Shigemoto, R., Huganir, R. L., Worley, P., and Craig, A. M. (2000) Neuron 28, 485-497[CrossRef][Medline] [Order article via Infotrieve] |
| 42. |
Dev, K. K.,
Nakajima, Y.,
Kitano, J.,
Braithwaite, S. P.,
Henley, J. M.,
and Nakanishi, S.
(2000)
J. Neurosci.
20,
7252-7257 |
| 43. | El Far, O., Airas, J., Wischmeyer, E., Nehring, R. B., Karschin, A., and Betz, H. (2000) Eur. J. Neurosci. 12, 4215-4221[CrossRef][Medline] [Order article via Infotrieve] |
| 44. |
Staudinger, J.,
Lu, J.,
and Olson, E. N.
(1997)
J. Biol. Chem.
272,
32019-32024 |
| 45. | Flor, P. J., Van Der Putten, H., Ruegg, D., Lukic, S., Leonhardt, T., Bence, M., Sansig, G., Knopfel, T., and Kuhn, R. (1997) Neuropharmacology 36, 153-159[CrossRef][Medline] [Order article via Infotrieve] |
| 46. | Corti, C., Restituito, S., Rimland, J. M., Brabet, I., Corsi, M., Pin, J. P., and Ferraguti, F. (1998) Eur. J. Neurosci. 10, 3629-3641[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
E. Kostenis, L. Martini, J. Ellis, M. Waldhoer, A. Heydorn, M. M. Rosenkilde, P. K. Norregaard, R. Jorgensen, J. L. Whistler, and G. Milligan A Highly Conserved Glycine within Linker I and the Extreme C Terminus of G Protein {alpha} Subunits Interact Cooperatively in Switching G Protein-Coupled Receptor-to-Effector Specificity J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 78 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Heydorn, R. J. Ward, R. Jorgensen, M. M. Rosenkilde, T. M. Frimurer, G. Milligan, and E. Kostenis Identification of a Novel Site within G Protein {alpha} Subunits Important for Specificity of Receptor-G Protein Interaction Mol. Pharmacol., August 1, 2004; 66(2): 250 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Havlickova, J. Blahos, I. Brabet, J. Liu, B. Hruskova, L. Prezeau, and J.-P. Pin The Second Intracellular Loop of Metabotropic Glutamate Receptors Recognizes C Termini of G-protein {alpha}-Subunits J. Biol. Chem., September 12, 2003; 278(37): 35063 - 35070. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Pankevych, V. Korkhov, M. Freissmuth, and C. Nanoff Truncation of the A1 Adenosine Receptor Reveals Distinct Roles of the Membrane-proximal Carboxyl Terminus in Receptor Folding and G Protein Coupling J. Biol. Chem., August 8, 2003; 278(32): 30283 - 30293. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Millan, E. Castro, M. Torres, R. Shigemoto, and J. Sanchez-Prieto Co-expression of Metabotropic Glutamate Receptor 7 and N-type Ca2+ Channels in Single Cerebrocortical Nerve Terminals of Adult Rats J. Biol. Chem., June 20, 2003; 278(26): 23955 - 23962. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Simon, A. K. Filippov, S. Goransson, Y. H. Wong, C. Frelin, A. D. Michel, D. A. Brown, and E. A. Barnard Characterization and Channel Coupling of the P2Y12 Nucleotide Receptor of Brain Capillary Endothelial Cells J. Biol. Chem., August 23, 2002; 277(35): 31390 - 31400. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||